MedPath

IRIS Alfa Clinical Trial A Monocentric, Academic Clinical Trial Safety Study of a Prototype of a New Vitrectomy Device.

Not Applicable
Terminated
Conditions
Vitrectomy
Registration Number
NCT04409808
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Brief Summary

To perform a safety study on the prototype IRIS vitrectomy device.

Detailed Description

to determine the safety and effectiveness of the device.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
39
Inclusion Criteria
  • Patients that are scheduled for vitrectomy surgery, regardless of the indication
  • Both vitrectomy-only and combined phaco-vitrectomy surgeries
  • Primary or repeat vitrectomy
  • General or local anesthesia, or combination
  • All ages
  • Informed consent (from parents in patients <18 years old)
Exclusion Criteria
  • Unable to obtain informed consent from patient (or from parents in children)
  • No post-operative 8 week visit is anticipated

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
incidence of intra-operative adverse events that determine the safety of the surgeryIntraoperative (surgery day)

complications VTX: iatrogenic tear, lens touch, choroidal/subretinal/vitreous hemorrhage, infusion suprachoroidal, iatrogenic retina trauma, posterior capsule tear, corneal eptihelial damage, hyphema, corneal edema, iris trauma, nucleus fragment in vitreous, posterior capsule tear, retinal incarceration, zonulae rupture with vitreous prolapse, subretinal PFCL, suprachoroidal silicone oil, zonulae dialysis, lens exchange required, other IOL problem

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UZ Leuven

🇧🇪

Leuven, Vlaams Brabant, Belgium

UZ Leuven
🇧🇪Leuven, Vlaams Brabant, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.